Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

MI-773

Catalog No: tcsc2686

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1303607-07-9

Formula:
$C_{29}H_{34}Cl_2FN_3O_3$

Pathway:
Apoptosis

Target:
MDM-2/p53

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 53 mg/mL (94.22 mM)

Observed Molecular Weight:
562.5

Product Description

MI-773 is a new small molecule inhibitor of the **MDM2-p53** interaction, binds to **MDM2** with high affinity ($\mathbf{K_i}$=0.88 nM) and blocks

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

the p53-MDM2 interaction.

IC50 & Target: Ki: 0.88 nM (MDM2)[1]

In Vitro: MI-773 potently induces expression of p53 and its downstream targets p21, MDM2, and induces phosphorylation of p53 (serine 392) in low passage primary human ACC cells. Notably, MI-773 induces a dose-dependent increase in the fraction of apoptotic ACC cells and in the fraction of cells in the G1 phase of cell cycle (P[1]. MI-773 is an advanced synthetic small molecule inhibitor, displays high binding affinity against MDM2 (K_d=8.2 nM)[2].

In Vivo: MI-773 at 10 mg/kg modestly reduces the rate of tumor growth, whereas 100 mg/kg causes significant tumor regression. Control tumors reach an average of 1,000 mm^3 at 20 days of treatment, compare to an average volume of 600 mm^3 for the 10 mg/kg group and 30 mm^3 for the 100 mg/kg group. Kaplan-Meier analysis shows an increase in tumor failure, define as two times increase in tumor volume as compared to pretreatment volume (P=0.044), for vehicle-treated mice when compare to mice treated with 100 mg/kg MI-773[1].